Posts

Showing posts with the label BiotechandPharmaceuticals

Insurance stocks have fallen since UnitedHealthcare CEO killing

Image
[ad_1] A banner hanging from on overpass along the southbound lane of I-83 that says, "Deny Defend Depose Health Care 4 All." Lloyd Fox | Baltimore Sun | Tribune News Service | Getty Images Major insurance stocks have fallen more than 6% since their closing prices last Tuesday, the day before the deadly shooting of Brian Thompson, CEO of UnitedHealth Group 's insurance arm, in midtown Manhattan.  That includes UnitedHealth, CVS Health and Cigna , which operate three of the nation's largest private health insurers. Thompson, 50, led UnitedHealthcare, the largest private payer of health insurance benefits in the U.S.  Luigi Mangione , 26, is accused of fatally shooting Thompson outside the Hilton hotel in midtown Manhattan early Wednesday last week, as the CEO headed to UnitedHealth Group's investor day. Investigators have said Mangione was a critic of the health-care industry, a view some Americans sympathized with online in the days after Thompson's d...

Can you use expired Covid tests? What to know as cases rise, new variants emerge

Image
[ad_1] In this photo illustration, Abbott's at-home covid-19 rapid test kits are seen on display in Orlando. Paul Hennessy | LightRocket | Getty Images As Covid cases surge again in the U.S., Americans are digging out unused at-home tests that they stashed earlier on in the pandemic.  Many of those tests may have passed their expiration dates , but don't throw them away just yet.  The Food and Drug Administration has extended the expiration dates of many popular at-home test products, which means some of your old kits may still be safe to use. You can check by visiting a page on the FDA's website that lists expiration information for each test brand. "That's the first thing I would do before using an expired test or throwing it away," Andrew Pekosz, a professor at the Johns Hopkins Bloomberg School of Public Health, told CNBC. If the date has not changed, the FDA advises against using expired tests. Doing so increases the chance of an inaccurate tes...

Big drug company CEOs to testify at Senate Health committee on insulin prices

Image
[ad_1] In this photo illustration, an insulin pen manufactured by the Novo Nordisk company is displayed on March 14, 2023 in Miami, Florida. Joe Raedle | Getty Images News | Getty Images The top executives of the three drug companies that control 90% of the global insulin market will testify May 10 before the Senate Health Committee on lowering prices of their diabetes drugs, panel Chairman Sen. Bernie Sanders said Friday. Those companies — Eli Lilly , Novo Nordisk and Sanofi — had announced in March that they will slash prices of their most widely used insulin products by 70% or more. related investing news Sanders on Friday called that move an important step forward that was the result of "public outrage and strong grassroots efforts." But the Vermont independent added that Congress must ensure that insulin, whose price has increased by more than 1,000% since 1996, is affordable for everyone. "We must make certain, however, that those price reductions go in...

Healthy Returns: What to know about the latest round of Pfizer, Moderna Covid vaccines

Image
[ad_1] Moderna Covid-19 Vaccine mRNA 2024-2025 formula. Courtesy: Moderna A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. It's that time of the year again. A new round of Covid shots is on its way to Americans.  The Food and Drug Administration last week approved updated mRNA-based vaccines from Pfizer and Moderna amid a relatively large summer surge of the virus. Here's what you need to know, including how the shots are different this time around, who is eligible, where to get a vaccine and more.  What makes these shots different? U.S. health officials have long told patients to expect annual updates to Covid shots as the virus mutates into new strains that can dodge the immunity people develop from previous vaccinations or infections. It's similar to how the U.S. rolls out new flu shots each year.  This time, the shots fro...

FDA advisors raise doubts about seasonal updates to Covid vaccines as with flu shots

Image
[ad_1] A person receives a COVID-19 vaccination dose, during a free distribution of COVID-19 rapid test kits for those who received vaccination shots or booster shots, at Union Station on January 7, 2022 in Los Angeles, California. Mario Tama | Getty Images The U.S. Food and Drug Administration 's independent panel of advisors raised doubts about the need to "periodically" update Covid vaccines, noting that it's unclear if the virus is seasonal like the flu. Advisors on Thursday unanimously voted that new jabs for the fall should be monovalent — meaning they are designed against one variant of Covid — and target one of the omicron XBB strains . Those are now the dominant variants nationwide.  But the original voting question included language about whether the panel recommends a "periodic update" to Covid shots.  Dr. Peter Marks, head of the FDA's vaccine division, asked the panel's chair to strike the wording from the question after severa...

Healthy Returns: Higher medical costs are pinching insurers

Image
[ad_1] A UnitedHealth Group health insurance card is seen in a wallet, Oct.14, 2019. Lucy Nicholson | Reuters Good afternoon! Health insurers are feeling the squeeze as older patients head to the doctor more than expected. CVS , which owns health insurer Aetna, on Wednesday  slashed its full-year profit outlook , citing the potential for higher medical costs to bite into its profits. That warning came two weeks after insurance giant  Humana  cited the same factor as it issued a  dismal 2024 earnings guidance . Medical costs from Medicare Advantage patients have  spiked over the last year  as more older adults return to hospitals to undergo procedures they had delayed during the Covid pandemic, such as joint and hip replacements.  Medicare Advantage , a type of privately run health insurance plan contracted by Medicare, has long been a key source of growth and profits for the insurance industry.  More than half  of Medicare beneficiaries are enrolled in such plans, enticed by lower...

Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says

Image
[ad_1] The newly FDA approved Alzheimer's treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023.  Hannah Yoon | The Washington Post | Getty Images The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, according to new data released Tuesday by Japanese drugmaker Eisai .  The study results on Leqembi, which Eisai shares with Biogen , also found that a patient's Alzheimer's disease worsens after they stop treatment. Rates of adverse side effects associated with Leqembi, including brain bleeding and swelling, dropped after six months of treatment, Dr. Lynn Kramer, Eisai's chief clinical officer of deep human biology learning, told CNBC.  That decline is critical: Those side effects in the brain have raised concerns among some doctors and are the main reason a European drug regulator recommend...

Democratic attorneys general sue FDA to drop all remaining restrictions on abortion pill

Image
[ad_1] Boxes of mifepristone, the first pill given in a medical abortion, are prepared for patients at Women's Reproductive Clinic of New Mexico in Santa Teresa, U.S., January 13, 2023.  Evelyn Hockstein | Reuters A coalition of a dozen Democratic attorneys general sued the Food and Drug Administration on Friday to force the agency to drop all remaining restrictions on the abortion pill, the latest case in an escalating series of legal battles over access to the medication. The attorneys general asked a federal court in the eastern district of Washington to declare that the abortion pill, mifepristone, is safe and effective and that all remaining restrictions on the medication are unconstitutional. The lawsuit was led by Washington state Attorney General Bob Ferguson and Oregon's AG Ellen Rosenblum. The attorneys general of Arizona, Colorado, Connecticut, Delaware, Illinois, Michigan, Nevada, New Mexico, Rhode Island and Vermont were also part of the suit. The attorneys g...

Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook

Image
[ad_1] The launch of Eli Lilly 's weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said Friday. Weekly Zepbound prescriptions totaled 7,700 in the week ended Dec. 8, its fourth on the U.S. market, according to Jefferies, which cited data compiled by health-care analytics firm IQVIA. That is more than Novo Nordisk 's Wegovy — currently the most popular obesity drug in the country — had in its fourth week after being approved in 2021, Jefferies concluded. "Zepbound has shown strong launch momentum in the weeks following its first prescription recorded," the analysts wrote in a research note. That's an encouraging finding for investors, given it will be more than a month before Eli Lilly reports earnings with formal revenue contributions from its much-hyped obesity drug. The Club holding typically reports fourth-quarter results in late January or early February. To be sure...

Health-care ETFs tend to rise around next week's annual JPMorgan conference. Here's what to know

Image
[ad_1] Next week is one of the biggest of the year for health-care investors, and it has historically been a good time to own ETFs that track the industry. The 2023 JPMorgan Health Care Conference is set to kick off next Monday in San Francisco. The event features keynote speeches from the CEOs of Sage Therapeutics and Eli Lilly , as well as presentations from dozens of other health-care and biotech companies. The conference typically sees many companies preannounce quarterly results, revise outlooks and update investors about clinical trials. While those updates can break both ways for individual companies, they have recently been good news for the sector as a whole. Over the past five years, many of the biggest ETFs in health care and biotech have seen an average positive return in the first half of January, when the conference is typically held. The three funds below — the SPDR S & P Biotech ETF (XBI) , the Health Care Select Sector SPDR Fund (XLV) and the iShares U.S. Medi...

AI, wearables and more — these markets are booming as the world ages. The pros share 4 stock picks

Image
[ad_1] The world is aging rapidly, and there are more and more ways to invest in this theme. Shams Afzal, managing director at Carnegie Investment Counsel, noted that 17% of the U.S. population is now over the age of 65, and that proportion is expected to grow higher. And the demographics of that age group is changing. There's been a "marked jump" in education levels — just 5% of those aged above 65 were degree holders in 1950, much lower than the 29% in 2018, Afzal said, citing Population Reference Bureau statistics. The gender gap in terms of mortality has also narrowed, from seven years in 1990 to five years in 2017, he said. "The aging population discussion in recent years has mostly revolved around future challenges to labor productivity and its economic growth implications," he said. "We see meaningful efforts by companies large and small, working to enhance the quality of life for individuals in this age group," Afzal, also a portfolio mana...

Moderna halts plans to build Kenya vaccine plant as Covid shot demand plunges

Image
[ad_1] A nurse prepares a dose of Moderna Covid-19 vaccine at Oltepesi Dispensary in Kajiado, Kenya, on September 9, 2021. Patrick Meinhardt | AFP | Getty Images Moderna on Thursday said it has paused plans to build a vaccine-manufacturing site in Kenya after a steep drop in demand for its Covid vaccines . The biotech company said it has not received any vaccine orders for Africa since 2022 and has taken more than $1 billion in losses and write-downs related to the cancellation of previous orders from the continent. Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine-manufacturing footprint. The company's business took a major hit last year as demand for those jabs waned worldwide, with people relying less on protective vaccines and treatments against the virus. Shares of Moderna fell 45% last year, but the stock is up around 6% this year. In March 2022, the company said it would invest about $500 million in the Kenyan site and...